Antiretroviral therapy (ART) is the drug treatment that makes HIV undetectable. Most people take a combination of two or three medications, often combined into a single daily pill, that work together to stop the virus from replicating. When taken consistently, these drugs reduce the amount of HIV in the blood to fewer than 200 copies per milliliter, a level so low that standard lab tests can’t detect it.
How ART Stops HIV From Replicating
No single drug makes HIV undetectable on its own. ART uses a combination of medications from different drug classes, each targeting a different step in the virus’s life cycle. The two most important classes in today’s first-line treatments are integrase strand transfer inhibitors (INSTIs) and nucleoside reverse transcriptase inhibitors (NRTIs).
INSTIs block an enzyme HIV needs to insert its genetic code into your cells’ DNA. Without this step, the virus can’t hijack your cells to make copies of itself. NRTIs work earlier in the process: they act as decoy building blocks that get incorporated into the growing chain of viral DNA, then stop the chain from extending any further. By attacking the virus at multiple points simultaneously, the combination makes it extremely difficult for HIV to develop resistance to treatment.
The Most Commonly Prescribed Regimens
Current U.S. treatment guidelines recommend starting with a second-generation INSTI combined with one or two NRTIs. The three regimens recommended for most people with HIV are:
- Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine): A single pill containing three drugs. It’s one of the most widely prescribed options due to its effectiveness, tolerability, and high barrier to resistance.
- Dolutegravir plus two NRTIs: Dolutegravir paired with tenofovir and either emtricitabine or lamivudine. This can be taken as two pills or, in some formulations, as one.
- Dovato (dolutegravir/lamivudine): A two-drug, single-pill regimen. It’s an option for people whose viral load is under 500,000 copies per milliliter and who don’t have hepatitis B.
Another combination, Triumeq (dolutegravir/abacavir/lamivudine), is recommended for certain clinical situations rather than as a default first choice. All of these regimens have strong evidence behind them from randomized controlled trials showing durable viral suppression.
Injectable Options
For people who prefer not to take daily pills, long-acting injectable treatments are now available. Cabotegravir plus rilpivirine (sold as Cabenuva) is an injectable regimen given every two months for HIV treatment. It maintains viral suppression without the need for daily oral medication. This option is typically for people who have already achieved an undetectable viral load on oral ART and want to switch.
How Long It Takes to Become Undetectable
Most people who start ART and take it consistently reach an undetectable viral load within one to six months. The exact timeline depends on how high the viral load was at the start of treatment and how the body responds to the specific regimen. Your healthcare provider will monitor your viral load with regular blood tests during this period to confirm the drugs are working.
Once you reach undetectable, staying there depends entirely on adherence. Missing doses or stopping treatment can cause the virus to rebound, sometimes within weeks. Worse, inconsistent use gives the virus a chance to mutate and develop resistance to the medications, which can limit future treatment options.
What “Undetectable” Actually Means
Viral suppression is officially defined as having fewer than 200 copies of HIV per milliliter of blood. “Undetectable” goes a step further: it means the viral load is below the detection limit of standard lab tests, typically under 20 to 50 copies per milliliter depending on the test used. This doesn’t mean HIV is gone from the body. The virus persists in a latent reservoir inside certain immune cells, which is why stopping medication leads to viral rebound.
Some people who are otherwise well-suppressed experience what’s called a viral blip, a brief, low-level spike in detectable virus (between 20 and 200 copies per milliliter) that shows up on routine blood work. Blips can result from normal test variation, a minor illness triggering immune activation, or low-level viral activity from the latent reservoir. A single blip doesn’t necessarily mean treatment is failing, but repeated blips may reflect ongoing activity from the reservoir and warrant closer monitoring.
Undetectable Means Untransmittable
One of the most important facts about reaching and maintaining an undetectable viral load: you cannot sexually transmit HIV to a partner. This principle, known as U=U (Undetectable = Untransmittable), is backed by large-scale clinical evidence.
The PARTNER study, published in The Lancet, followed 972 gay male couples where one partner had HIV and the other did not. Over 1,593 couple-years of follow-up during which couples reported condomless sex, there were zero transmissions from partners who maintained viral suppression. Fifteen of the HIV-negative partners did acquire HIV during the study period, but genetic testing confirmed every one of those infections came from someone outside the relationship, not from the suppressed partner. Combined with earlier data from heterosexual couples, the evidence shows the risk of transmission when viral load is suppressed is effectively zero.
This finding has reshaped how HIV is managed and understood. Reaching undetectable isn’t just about personal health. It eliminates the risk of passing the virus to sexual partners, making effective treatment one of the most powerful prevention tools available.